2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study
Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study. Cancer 2017, 123: 3754-3762. PMID: 28621841, PMCID: PMC6540984, DOI: 10.1002/cncr.30814.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaRisk of deathSupportive careEnd Results-Medicare databaseOlder adultsMedian OS timeOverall survival benefitCohort of patientsProportional hazards modelUse of HMAsMedian OSAgent therapySurvival benefitOS timeCMML patientsMyelomonocytic leukemiaHazards modelHMA treatmentPatientsTemporal improvementSecondary analysisPropensity scoreLimited evidenceSurvival changesApproval
2011
Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy
Lowery M, Klimstra D, Shia J, Yu K, Allen P, Brennan M, O'Reilly E. Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. The Oncologist 2011, 16: 1714-1720. PMID: 22042785, PMCID: PMC3248770, DOI: 10.1634/theoncologist.2011-0231.Peer-Reviewed Original ResearchConceptsAcinar cell carcinomaOverall survivalCell carcinomaGermline mutationsMetastatic acinar cell carcinomaCase of acinar cell carcinomaPartial response to chemotherapyMemorial Sloan-Kettering Cancer CenterBRCA1 germline mutationsMedian overall survivalInstitutional review board approvalResponse to chemotherapyReview board approvalResectable diseaseStable diseaseSystemic chemotherapyRare malignancySystemic therapyRare neoplasmsMedian ageOS timePancreatic adenocarcinomaConsecutive casesPancreatic neoplasmsColorectal carcinoma
2006
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors
Kobayashi K, Gupta S, Trent JC, Vauthey J, Krishnamurthy S, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE, Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. Cancer 2006, 107: 2833-2841. PMID: 17096432, DOI: 10.1002/cncr.22336.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationGastrointestinal stromal tumorsUse of imatinibOverall survivalOS timeLiver diseaseStromal tumorsTumor responseMetastatic gastrointestinal stromal tumorsExtensive liver involvementMedian OS timeObjective tumor responseMedian PFS timeProgression-free survivalKaplan-Meier methodMajority of patientsDurable tumor responsesExtrahepatic diseaseOS ratesRadiologic responseStable diseaseDisease stabilizationPFS timeExtrahepatic metastasesLiver involvementNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic value
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply